A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Linsitinib (Primary)
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
- Sponsors Sling Therapeutics
Most Recent Events
- 03 Nov 2023 New trial record